全文获取类型
收费全文 | 64篇 |
免费 | 1篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 1篇 |
基础医学 | 2篇 |
临床医学 | 3篇 |
内科学 | 16篇 |
特种医学 | 1篇 |
外科学 | 17篇 |
药学 | 2篇 |
肿瘤学 | 27篇 |
出版年
2022年 | 1篇 |
2021年 | 2篇 |
2020年 | 2篇 |
2019年 | 1篇 |
2018年 | 3篇 |
2017年 | 1篇 |
2016年 | 3篇 |
2015年 | 3篇 |
2014年 | 1篇 |
2013年 | 3篇 |
2012年 | 5篇 |
2011年 | 11篇 |
2009年 | 1篇 |
2008年 | 5篇 |
2007年 | 4篇 |
2006年 | 6篇 |
2004年 | 1篇 |
2002年 | 3篇 |
2001年 | 2篇 |
2000年 | 6篇 |
1999年 | 1篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1987年 | 1篇 |
1986年 | 1篇 |
排序方式: 共有69条查询结果,搜索用时 125 毫秒
51.
Rutika Mehta Jessica Frakes Jongphil Kim Andrew Nixon Yingmiao Liu Lauren Howard Maria E Martinez Jimenez Estrella Carballido Iman Imanirad Julian Sanchez Sophie Dessureault Hao Xie Seth Felder Ibrahim Sahin Sarah Hoffe Mokenge Malafa Richard Kim 《The oncologist》2022,27(8):621
BackgroundNeoadjuvant chemoradiation with fluoropyrimidine followed by surgery and adjuvant chemotherapy has been the standard treatment of locally advanced stages II and III rectal cancer for many years. There is a high risk for disease recurrence; therefore, optimizing chemoradiation strategies remains an unmet need. Based on a few studies, there is evidence of the synergistic effect of VEGF/PDGFR blockade with radiation.MethodsIn this phase I, dose-escalation and dose-expansion study, we studied 3 different dose levels of lenvatinib in combination with capecitabine-based chemoradiation for locally advanced rectal cancer.ResultsA total of 20 patients were enrolled, and 19 were eligible for assessment of efficacy. The combination was well tolerated, with an MTD of 24 mg lenvatinib. The downstaging rate for the cohort and the pCR was 84.2% and 37.8%, respectively. Blood-based protein biomarkers TSP-2, VEGF-R3, and VEGF correlated with NAR score and were also differentially expressed between response categories. The NAR, or neoadjuvant rectal score, encompasses cT clinical tumor stage, pT pathological tumor stage, and pN pathological nodal stage and provides a continuous variable for evaluating clinical trial outcomes.ConclusionThe combination of lenvatinib with capecitabine and radiation in locally advanced rectal cancer was found to be safe and tolerable, and potential blood-based biomarkers were identified.Clinical Trial Registration NCT02935309相似文献
52.
53.
54.
55.
56.
Alexandra Gangi Jehan Shah Nathan Hatfield Johnna Smith Jennifer Sweeney Junsung Choi Ghassan El-Haddad Benjamin Biebel Nainesh Parikh Bulent Arslan Sarah E. Hoffe Jessica M. Frakes Gregory M. Springett Daniel A. Anaya Mokenge Malafa Dung-Tsa Chen Yunyun Chen Richard D. Kim Bela Kis 《Journal of vascular and interventional radiology : JVIR》2018,29(8):1101-1108
Purpose
To evaluate the efficacy and safety of transarterial yttrium-90 glass microsphere radioembolization in patients with unresectable intrahepatic cholangiocarcinoma (ICC).Materials and Methods
Retrospective review of 85 consecutive patients (41 men and 44 women; age, 73.4 ± 9.3 years) was performed. Survival data were analyzed by the Kaplan-Meier method, Cox regression models, and the log-rank test.Results
Median overall survival (OS) from diagnosis was 21.4 months (95% confidence interval [CI]: 16.6–28.4); median OS from radioembolization was 12.0 months (95% CI: 8.0–15.2). Seven episodes of severe toxicity occurred. At 3 months, 6.2% of patients had partial response, 64.2% had stable disease, and 29.6% had progressive disease. Median OS from radioembolization was significantly longer in patients with Eastern Cooperative Oncology Group (ECOG) scores of 0 and 1 than patients with an ECOG score of 2 (18.5 vs 5.5 months, P = .0012), and median OS from radioembolization was significantly longer in patients with well-differentiated histology than patients with poorly differentiated histology (18.6 vs 9.7 months, P = .012). Patients with solitary tumors had significantly longer median OS from radioembolization than patients with multifocal disease (25 vs. 6.1 months, P = .006). The absence of extrahepatic metastasis was associated with significantly increased median OS (15.2 vs. 6.8 months, P = .003). Increased time from diagnosis to radioembolization was a negative predictor of OS. The morphology of the tumor (mass-forming or infiltrative, hyper- or hypo-enhancing) had no effect on survival. Post-treatment increased cancer antigen 19-9 level, increased international normalized ratio, decreased albumin, increased bilirubin, increased aspartate aminotransferase, and increased Model for End-Stage Liver Disease score were significant predictors of decreased OS.Conclusions
These data support the therapeutic role of radioembolization for the treatment of unresectable ICC with good efficacy and an acceptable safety profile. 相似文献57.
58.
Khaldoun Almhanna Christopher L Cubitt Shumin Zhang Sabiha Kazim Kazim Husain Dan Sullivan Said Sebti Mokenge Malafa 《Cancer biology & therapy》2013,14(10):932-936
Background
Several molecularly-targeted agents are being evaluated in gastric cancer cell lines. In this study we evaluated the synergistic potential of MK-2206, an oral potent allosteric Akt inhibitor, in combination with chemotherapeutic agents in human gastric cancer cell lines.
Materials and Methods
We evaluated effects of MK-2206 on cell growth and cell signaling using a panel of gastric cancer cell lines AGS, SNU-1 and SNU 16. The analysis of drug combinations was conducted by using CellTiter-Blue™ Cell Viability Assay which yielded the combination index (CI). MK-2206 and representative chemotherapy agent were further evaluated regarding their effects on Akt inhibition and downstream targets using western blots probed with the appropriate antibodies. We assessed the combination of MK-2206 and chemotherapy in three different treatment sequences.
Results
We demonstrated in vitro synergistic efficacy of MK-2206 when combined with carboplatinum and paclitaxel in the three cell lines examined. Efficacy was dose dependent. We assessed the combination of MK-2206 and carboplatinum/paclitaxel in three different treatment sequences; 24 h of exposure to combination chemotherapy followed by a 48 h exposure to MK-2206 resulted in the highest synergistic antiproliferative effect in all cell lines. On the other hand, the reverse sequence (MK-2206 followed by chemotherapy) and the concurrent treatment schedule were slightly synergistic or additive as well. The effects of MK-2206 on p-Akt and other downstream targets was reported.
Conclusions
Our findings suggest that Akt inhibition augments the efficacy of existing gastric cancer therapeutics (carboplatinum and paclitaxel); thus, MK-2206 is a promising agent to treat gastric cancer patients who receive these cytotoxic agents. The magnitude of synergy depended on the treatment sequence; a schedule of MK-2206 dosed before or concurrently with chemotherapy was not as effective as being dosed after chemotherapy. Further experiments addressing MK-2206’s mechanism of action in combination with chemotherapy are needed. 相似文献
59.
Farma JM Santillan AA Melis M Walters J Belinc D Chen DT Eikman EA Malafa M 《Annals of surgical oncology》2008,15(9):2465-2471
Background The role of fusion positron emission tomography/computed tomography scans (PET/CT) in staging of patients with pancreatic
neoplasms (PN) is poorly defined. PET/CT may serve as an adjunct to standard imaging by increasing occult metastases detection.
The purpose of this study was to assess the additional value, in relation to computed tomography (CT), of PET/CT imaging for
patients with PN.
Methods Eighty-two patients with potentially resectable PN underwent staging with PET/CT and CT of the chest and abdomen. Sensitivity
of diagnosing pancreatic cancer by PET/CT avidity was evaluated. The sensitivity of detecting metastases was compared between
PET/CT, standard CT, and the combination of PET/CT and CT. The impact of PET/CT on patient management was estimated by calculating
the percentage of patients whose treatment plan was altered due to PET/CT.
Results The sensitivity and specificity of PET/CT in diagnosing pancreatic cancer were 89% and 88%, respectively. Sensitivity of detecting
metastatic disease for PET/CT alone, standard CT alone, and the combination of PET/CT and CT were 61%, 57%, and 87%, respectively.
Findings on PET/CT influenced the clinical management in seven patients (11%), two with a supraclavicular lymph node (LN),
two occult liver lesions, two peritoneal implants, and one peri-esophageal LN.
Conclusion This study evaluated PET/CT in the initial work-up of patients with PN. PET/CT increased sensitivity (87%) for detection of
metastatic disease when combined with standard CT. In invasive cancer, PET/CT changed the management in 11% of our patients.
PET/CT should be considered in the initial work-up of patients with potentially resectable pancreatic lesions. 相似文献
60.
Jensen EH Kvols L McLoughlin JM Lewis JM Alvarado MD Yeatman T Malafa M Shibata D 《Annals of surgical oncology》2007,14(2):780-785
BACKGROUND: Cytoreductive therapy for metastatic carcinoid provides symptomatic relief and improvement in overall survival. We evaluated whether CgA and 5HIAA could predict symptomatic relief and control of disease progression after cytoreductive surgery. METHODS: We retrospectively reviewed 70 patients who underwent cytoreductive surgery for neuroendocrine hepatic metastases between 1996 and 2005. Twenty-two patients had pre and post-operative CgA and/or 5HIAA levels measured. Reduction of biomarkers following cytoreduction was correlated with patient symptoms and progression of disease following surgery. RESULTS: Our study consisted of 14 males and 8 females with a mean age of 55 (+/-12 years). Median follow-up was 18 months (range 5-64 months). Six patients (26.1%) had complete (R0) cytoreduction, while 4 (17.4%) and 13 (56.5%) had microscopic (R1) and gross (R2) disease remaining. All patients reported improvements in their symptoms, with 12 (54.5%) reporting complete resolution (CR) and 10 (45.5%) reporting partial resolution (PR). Reduction of CgA of >or= 80% was highly predictive of complete resolution of symptoms (P = 0.007) and stabilization of disease (P = 0.034). Reduction of 5HIAA levels of >or= 80% (or normalization) was predictive of symptomatic relief, but not progression of disease (P = 0.026 and P = 0.725). Five of six patients who had R0 resections had CR and were free of disease at last follow-up (median 24.5 months, range: 11-48, P = 0.002). CONCLUSIONS: We conclude that >or= 80% reduction in CgA level following cytoreductive surgery for carcinoid tumors is predictive of subsequent symptom relief and disease control. Substantial reduction in CgA is associated with improved patient outcomes, even after incomplete cytoreduction. 相似文献